Voyager Therapeutics, Inc.

For the period ended Dec 31, 2025. Filed Mar 9, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 9, 2026

VYGR$1.83-8.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Stockholders’ Equity

(amounts in thousands, except share data)


· · · · · · · · · · · · · · · · ·
· · · · · · · · · · Accumulated · · · · · ·
· · · · · · · Additional · · Other · · · · ·
· · Common Stock · · Paid-In · · Comprehensive · · Accumulated · · Stockholders’
· · Shares · · Amount · · Capital · · (Loss) Income · · Deficit · · Equity
Balance at December 31, 2022	38,613,891	$38	$452,713	$(219)	$(393,512)	$59,020
Exercises of vested stock options	385,655	1	1,851	—	—	1,852
Vesting of restricted stock units	531,560	—	—	—	—	—
Issuance of common stock in connection with the 2023 Neurocrine Collaboration Agreement	4,395,588	5	31,116	—	—	31,121
Issuance of common stock under ESPP	111,639	—	959	—	—	959
Stock-based compensation expense	—	—	10,867	—	—	10,867
Unrealized gain on available-for-sale securities, net of tax	—	—	—	171	—	171
Net income	—	—	—	—	132,330	132,330
Balance at December 31, 2023	44,038,333	$44	$497,506	$(48)	$(261,182)	$236,320
Exercises of vested stock options	106,831	—	388	—	—	388
Vesting of restricted stock units	515,303	1	—	—	—	1
Issuance of common stock in connection with the 2023 Novartis Stock Purchase Agreement	2,145,002	2	19,303	—	—	19,305
Issuance of common stock and pre-funded warrants in connection with underwritten public offering	7,777,778	8	93,465	—	—	93,473
Issuance of common stock under ESPP	148,069	—	1,172	—	—	1,172
Stock-based compensation expense	—	—	14,462	—	—	14,462
Unrealized loss on available-for-sale securities, net of tax	—	—	—	(359)	—	(359)
Net loss	—	—	—	—	(65,002)	(65,002)
Balance at December 31, 2024	54,731,316	$55	$626,296	$(407)	$(326,184)	$299,760
Exercises of vested stock options	91,489	1	266	—	—	267
Vesting of restricted stock units	691,107	—	—	—	—	—
Issuance of common stock under ESPP	201,404	—	549	—	—	549
Issuance of common stock from the exercise of pre-funded warrants	3,332,544	3	(3)	—	—	—
Stock-based compensation expense	—	—	14,787	—	—	14,787
Unrealized gain on available-for-sale securities, net of tax	—	—	—	439	—	439
Net loss	—	—	—	—	(119,721)	(119,721)
Balance at December 31, 2025	59,047,860	$59	$641,895	$32	$(445,905)	$196,081

The accompanying notes are an integral part of these consolidated financial statements

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.